Bioavailability of Long Acting Capsules of Melatonin in Mexican Healthy Volunteers

Mireya López-Gamboa1*, Juan Salvador Canales-Gómez2, Teresita de Jesús Castro Sandoval1, Emmanuel Núñez Tovar1, Maricela Alonso Mejía1, Maria de los Ángeles Melchor Baltazar1 and José Antonio Palma-Aguirre1
1Centro de Estudios Científicos Clínicos Pharma, S.A. de C.V., Mexico City, Mexico
2Productos Medix S.A. de C.V., Mexico City, Mexico

Keywords: Melatonin; Bioavailability; human; HPLC; MS-MS; Long acting capsules

Introduction

Melatonin (N-acetyl-5-methoxytryptamine) is a small lipophile molecule that is essentially secreted by the pineal gland and its synthesis shows a circadian pattern (Weaver et al., 1993; Jung and Ahmad, 2006). The neurohormone is produced during the dark phase of the day-night cycle by the pineal gland in a wide range of species (Fourtillan et al., 2001). In addition to the pineal gland, melatonin is also synthesized in the retina, bone marrow, gastrointestinal tract, and bile. It has a several functions including regulation of the reproductive axis (Tamarkin et al., 1985; Lang, 1986; Reiter, 1991) regulation of circadian rhythms (Cassone, 1990; Weaver et al., 1993) and antioxidant activity (Reiter et al., 1994).

During the day the serum endogenous melatonin concentration is low (10-20 pg/mL), at night reach peak concentrations (80-150 pg/mL) between midnight and 3:00 am. The half-life of melatonin in the serum is 30 to 60 minutes (Waldhauser et al., 1984; Mallo et al., 1990; Cavallo and Ritschel, 1996). In the blood, 50% to 75% of melatonin is bound reversibly to albumin and glycoproteins. Up to 60% of an oral dose has First-pass metabolism in the liver cytochrome P450 enzyme CYP1A2 (Waldhauser et al., 1984; Lane and Moss, 1985). Recent studies have indicated that the pituitary hormone melatonin is a selective substrate for CYP1A2 (Facciolá et al., 2001; Härtert et al., 2001). Mendoza-Cantú and colleagues investigated the frequency of CYP1A2 5'-flanking region in Mexicans and they found that frequencies are higher than those previously reported for other human populations (Mendoza-Cantú et al., 2004).

The oral bioavailability of immediate release melatonin is about 3% to 7% (Waldhauser et al., 1984; Lane and Moss, 1985). The apparent volume of distribution reported in several studies has discrepancy. Fourtillan and colleagues reported a volume of distribution at steady state of 0.99 L/kg (Fourtillan et al., 2001), whereas Mallo and colleagues reported a volume of distribution of 35 L (Mallo et al., 1990). In contrast, Goldberg and colleagues reported a very high volume of distribution of 6877 ± 4522 L, with a variation coefficient of 66% (Goldberg et al., 1997).

According to short half life time of melatonin, there are several studies with the immediate release formulation that shows a high variability in pharmacokinetics (PK) results (Waldhauser et al., 1984; Lane and Moss, 1985; Mallo et al., 1990; Goldberg et al., 1997; Fourtillan et al., 2001), however, a long acting formulation could reduce this variability in order to have better therapeutic response.

The aim of this study was to investigate the pharmacokinetic profile of long acting melatonin in Mexicans with special reference in comparing these pharmacokinetics parameters with other populations.

Subjects and Methods

The study protocol was approved by the ethics and research committees of the Centro de Estudios Científicos y Clínicos Pharma S. A. de C. V. (Amores #320; Col. Del Valle; Del. Benito Juarez; Mexico, D. F. Mexico City) in June 20, 2009, prior to trial initiation. The study was carried out in accordance with the principles of the

Abstract

Melatonin is a molecule that is essentially secreted by the pineal gland. The oral bioavailability of immediate release melatonin is low, and several pharmacokinetic parameters have a high variability in Cmax, clearance and volume of distribution.

The aim of this study was to investigate the bioavailability profile of long acting melatonin in Mexican. Twelve healthy volunteers participated into the study. After 12 hour overnight fast, subjects received a single capsule of long acting of melatonin 5 mg dose. For the pharmacokinetic analysis, blood samples were drawn at baseline, 0.25, 0.50, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0 and 24.0 hours after dosing.

The pharmacokinetic values were Cmax of 8.768 ± 7.043 nmol/L, Tmax of 2.7 ± 0.77 h, AUC0-t of 29.814 ± 24.931 h ng/mL, AUC0-∞ of 38.537 ± 24.658 h ng/mL, Cl of 185.293 ±121.806 L/h, Vd of 451.370 ± 510.039 L and t½ of 1.509 ± 0.768 h.

The pharmacokinetic values of long acting melatonin of our study showed a high variability in Cmax, clearance, half-life time and apparent volume of distribution in Mexican volunteers, and there are consistent with the great variability reported in other populations that used the short acting melatonin.

Keywords: Melatonin; Bioavailability; human; HPLC; MS-MS; Long acting capsules
Declarations of Helsinki and its amendments and the International Conference of Harmonisation Guidelines for Good Clinical Practices. Beforehand to start the study, the clinical investigator informed the subjects of all aims, methods, expected study duration, anticipated risks and discomfort it could entail, and a written informed consent was obtained from each subject.

Subjects selection and clinical procedures

Twelve healthy volunteers (six females and six males), aged between 18 and 55 years were included based on their medical history, clinical examination results, and routine laboratory tests. Subjects with HIV or hepatitis B or C virus were excluded. All healthy volunteers were selected from information’s database of the Centro de Estudios Científicos y Clinicos Pharma S. A. de C. V., Mexico City, Mexico. All eligible subjects provided written informed consent for participation in the study.

Study design and clinical procedures

A single, open-label, one sequence, single dose design was used. The subjects arrived at the clinical Unit the day before to beginning the study and they were fasted for 12 hours overnight before drug administration. A single long-acting capsule of melatonin 5mg (CRONOCAPS®, manufactured by Productos Medix, S. A. de C. V.) was given with 250 mL of water to each subject. Blood samples were drawn at baseline time (before drug study administration) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0 and 24.0 hours after drug study administration. The Blood samples (6 mL) were collected in the following manner: a 20-G catheter (Jelco® Plus, Medex Medical Ltd., Ascot, United Kingdom) was placed in a suitable forearm vein and the blood sample was drawn into a heparinized vacuum tube (Vacutainer®, Becton-Dickinson and Company, Franklin Lakes, New Jersey, USA). Plasma was obtained by centrifugation (2000 g for 10 minutes at room temperature) and was stored frozen at -70°C until it was analyzed by HPLC with MS-MS detector.

Tolerability

Tolerability was assessed by monitoring vital signs (blood pressure, heart rate, body temperature) at baseline, 4.5, 11.5 and 23.5 hours after drug administration. As well subjects were interviewed as regards the potential of adverse events (AEs) during the whole study.

Determination of plasma melatonin concentrations

Chemicals: Melatonin was donated by Productos Medix S.A. de C.V.; Venlafaxine were obtained from European Directorate for the Quality of Medicines & Health Care. Water (HPLC grade) was obtained by System Millipore Elix 5/Milli Q; methanol (MeOH HPLC grade) and ether anhydrous, hexane and formic acid (grade reactive), obtained by System Millipore Elix 5/Milli Q; methanol (MeOH HPLC grade) was obtained from Sigma–Aldrich (St. Louis, USA). Plasma was obtained by centrifugation (2000 g for 10 minutes at room temperature) and was stored frozen at -70°C.

Chromatographic conditions: The HPLC (Alliance 2690 Waters) was coupled to a mass spectrometer Quattro micro. The chromatographic conditions were: column Zorbax eclipse XDB-C18, 2.1 x 50 mm, 5 μm; ammonium formiate 5 mM pH 3.5 ± 0.05: MeOH (50:50 v/v) was used as mobile phase; the injection volume was 5 μL; the flow rate was maintained constant at 0.3 mL/min; the column temperature was 25°C; the retention times were between 0.7 to 1.0 minutes for melatonin and between 1.0 to 1.3 minutes for venlafaxine (internal standard).

Preparation of calibration standards and quality:

- Control samples: In order to prepare stock standard solution of Melatonin, 10 mg of melatonin was dissolved in 20 mL methanol-water (50:50, v/v). The stock solution was then further diluted with methanol-water (50:50, v/v) in order to obtain the different working solutions, from which the spiked plasma samples were prepared by appropriate dilution on ranging 2.5, 5.0, 10.0, 20.0, 40.0, 60.0, 70.0, 90.0 ng/mL. Quality control samples were prepared at low (7.5 ng/mL), medium (50.0 ng/mL) and high (80.0 ng/mL) concentrations in the same way as the plasma samples for calibration.

Sample preparation:

The extraction method consisted in a liquid-liquid extraction: Briefly, 500μL of plasma was mixed with 25μL of internal standard solution (venlafaxine, 200ng/mL), 75μL methanol-water (50:50, v/v), and 4mL of anhydro-hexane ether (80:20 v/v) was added. After vortexing (2 min) and centrifugation (1160 xg, 5 min) the aqueous phase was freeze 10 minutes at -70°C; the organic phase was evaporated to dryness and the residue was dissolved in 10 mL of mobile phase.

Pharmacokinetics and statistical analysis

The pharmacokinetic analysis was Individual plasma concentration-time curves were constructed; Cmax and Tmax were directly obtained from the curve. AUC from time 0 (baseline) to 24 hours (AUC0-24) was calculated using the trapezoidal rule. From the terminal log-decay phase, elimination rate constant (ke) was estimated using linear regression, and t1/2 was estimated using the following equation:

\[ t_{1/2} = \ln 2 / k_e \]

where In was defined as the natural log; and extrapolation of AUC from baseline to infinity (AUC∞) was calculated as follows:

\[ AUC_{\infty} = AUC_{0-24} + (C_{sp} / k_e) \]

where Csp was defined as concentration at 24 hours.

Results

A total of 12 subjects were enrolled in the study. Subjects had the following characteristics: age range 21 to 46 years, mean weight of 64.5 kg, and mean height of 1.7 m (Table 1).

Safety

Some adverse effects occurred in the volunteers during the study after melatonin administration of a 5 mg long acting capsule as follows: one volunteer had mild headache one hour post-dose, other volunteer had mild headache 3 hours post-dose, and the last one had mild headache 7 hours post-dose. All adverse reactions disappeared spontaneously without drug medication. These adverse events were classified with probable association with the study drug.

Mild somnolence occurred in all volunteers, but it was not considered as an adverse event, because just is the therapeutic effect of melatonin.

Pharmacokinetic parameters

Mean and SD values of Cmax, Tmax, t1/2, AUC0-t, AUC0-24, AUC∞, Vd (clearance) and Vd (apparent volume of distribution) are shown in table 2.

Table 1: Descriptive statistics of demographic characteristics of the volunteers: n = 12.
Research Article

Pharmacokinetic values were \( C_{\text{max}} \) of 8.768 ± 7.043 ng/mL, \( T_{\text{max}} \) of 2.7 ± 0.77 h, AUC \(_{\text{0-24}}\) of 29.81 ± 24.93 hr.ng/mL, AUC \(_{\text{0-inf}}\) of 38.54 ± 24.66 hr.ng/mL, \( t_{\text{max}} \) of 2.79 ± 0.78 h, \( t_{1/2} \) of 1.51 ± 0.77 h, Vd (L) of 451.37 ± 510.04 L, and Cl (L/hr) of 185.29 ± 121.81 L/hr.

Table 2: Individual melatonin pharmacokinetic parameters after 5 mg administration in Mexican healthy volunteers. (ND. Not determined, due to lack of characterisation of the elimination phase).

<table>
<thead>
<tr>
<th>Number</th>
<th>Volunteer</th>
<th>( t_{1/2} ) (h)</th>
<th>Vd(L)</th>
<th>Cl (L/hr)</th>
<th>Cmax (ng/mL)</th>
<th>AUC (_{\text{0-24}}) (hr.ng/mL)</th>
<th>AUC (_{\text{0-inf}}) (hr.ng/mL)</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>8.77</td>
<td>7.04</td>
<td>80.33</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1.29</td>
<td>502.56</td>
<td>270.43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.09</td>
<td>387.86</td>
<td>252.67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2.72</td>
<td>1755.02</td>
<td>448.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>0.92</td>
<td>71.58</td>
<td>54.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>0.94</td>
<td>179.78</td>
<td>132.17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>1.03</td>
<td>268.42</td>
<td>180.76</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>1.24</td>
<td>224.36</td>
<td>125.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>2.94</td>
<td>487.36</td>
<td>114.97</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>1.44</td>
<td>185.59</td>
<td>89.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1.51</td>
<td>451.37</td>
<td>185.29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard deviation</td>
<td>0.77</td>
<td>510.04</td>
<td>121.81</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum</td>
<td>0.92</td>
<td>71.58</td>
<td>54.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum</td>
<td>2.94</td>
<td>1755.02</td>
<td>448.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CV%</td>
<td>50.92</td>
<td>113.00</td>
<td>65.74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pharmacokinetics parameters of long-acting capsules of melatonin (n=12).

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter</th>
<th>Mean</th>
<th>Standard deviation</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>( C_{\text{max}} ) (ng/mL)</td>
<td>8.77</td>
<td>7.04</td>
<td>80.33</td>
</tr>
<tr>
<td>AUC (_{\text{0-24}}) (hr.ng/mL)</td>
<td>29.81</td>
<td>24.93</td>
<td>83.62</td>
</tr>
<tr>
<td>AUC (_{\text{0-inf}}) (hr.ng/mL)</td>
<td>38.54</td>
<td>24.66</td>
<td>63.98</td>
</tr>
<tr>
<td>( t_{\text{max}} ) (hr)</td>
<td>2.79</td>
<td>0.78</td>
<td>27.76</td>
</tr>
<tr>
<td>( t_{1/2} ) (hr)</td>
<td>1.51</td>
<td>0.77</td>
<td>50.91</td>
</tr>
<tr>
<td>Vd (L)</td>
<td>451.37</td>
<td>510.04</td>
<td>113.00</td>
</tr>
<tr>
<td>Cl (L/hr)</td>
<td>185.29</td>
<td>121.81</td>
<td>65.74</td>
</tr>
</tbody>
</table>

Figure 1: Plasma profile of 5 mg long acting capsule’s melatonin (mean ± standard error).

After the oral administration of melatonin 5 mg dissolved in vehicle solution, Goldberg and colleagues (Goldberg et al., 1997) reported values of \( T_{\text{max}} \) of 0.5 ± 0.18 h, half life time of 0.91 ± 0.15 h, clearance of 5160 ± 3351 L/h, and volume of distribution of 6877 ± 4522 L. Melatonin has very large apparent volume of distribution and clearance values which implies a high first-pass metabolism and low oral bioavailability.

In the other hand, Fourtillan and colleagues (Fourtillan et al., 2000) reported pharmacokinetic parameters after oral administration of 5 mg of melatonin near three-fold greater in female subjects than in males, with large inter-individual variations. The mean of maximum plasma melatonin concentration \( C_{\text{max}} \) was found at 243.7 ± 124.6 pg/mL and 623.6+/−575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236 ± 107 pg.h/mL and 701 ± 645 pg.h/mL. The absolute bioavailability of melatonin was from 1 to 37%: mean was of 8.6 ± 3.9% and 16.8 ± 12.7% for male and female subjects, respectively. In our study we did not observe any gender differences.

De Muro and colleagues (DeMuro et al., 2000) reported that after oral melatonin tablets in doses of 2 and 4 mg showed poor absolute bioavailability, either due to poor oral absorption, large first-pass metabolism, or a combination of both. They assume that a saturation of first-pass metabolism probably occurs.

Racial and ethnic differences in drug-metabolizing ability associated with genetic or cultural/environmental factors are not only well recognized but also important in understanding inter-individual variability in drug responsiveness. There are reports about the pharmacokinetics of melatonin of oral and intravenous administrations (Waldhauser et al., 1984; Vakkuri et al., 1985; Mallo et al., 1990; DeMuro et al., 2000). Waldhauser and colleagues reported an elimination half-life of 0.80 h after oral administration of crystalline melatonin (80 mg) in gelatin capsules (Waldhauser et al., 1984). Lane and Moss reported a prominent first pass hepatic metabolism and reduced bioavailability for orally administered melatonin (Lane and Moss, 1985). Using clearance parameters, endogenous production rates for melatonin were determined for normal individuals and patients with cirrhosis. Normal melatonin production was 28.8 micrograms/day, while the production rate for cirrhotic patients was 12.3 micrograms/day, suggesting also a decrease in daily melatonin production.

In our study, \( C_{\text{max}} \) values were different to other publications. Goldberg and coworkers (Goldberg et al., 1997) reported a \( C_{\text{max}} \) value of 1841 ± 2316 pg/mL with a CV of 126%, whereas in our study we have a \( C_{\text{max}} \) value of 8.768 ± 7.043 ng/mL, with a CV of 80%. In our study, the apparent volume of distribution was of 451 ± 510 L with a very high coefficient of variation (CV) of 112%. This result is totally different than those published in diverse populations (Mallo et al., 1990; Goldberg et al., 1997; Fourtillan et al., 2001). These results in \( C_{\text{max}} \) and Vd are probably due to several factors, with special emphasis in the long acting formulation of melatonin used in our study and the CYP1A2 activity of our Mexican volunteers. Further clinical studies should be necessary in order to evaluate the therapeutic utility of his long-acting melatonin formulation.

Discussion

The pharmacokinetic values of long acting melatonin of our study showed a high variability in \( C_{\text{max}} \), clearance, half-life and apparent volume of distribution in Mexican volunteers, and there are consistent with the great variability reported in other populations that used the short acting melatonin.

Acknowledgements

The study was supported entirely by Laboratories Productos Medix S. A. de C. V., Mexico City, Mexico.

Conflict of Interest Statement

All the authors declare that we have not conflict of interest with the publication of this manuscript.
References


